Literature DB >> 9738005

Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis.

Y Yasuda1, S Masuda, M Chikuma, K Inoue, M Nagao, R Sasaki.   

Abstract

Although erythropoietin (Epo) has been shown to possess in vitro angiogenic activity, its physiological significance has not been demonstrated. Normally angiogenesis does not occur actively in adults but an exception is the female reproductive organ. In the uterine endometrium, angiogenesis takes place actively for supporting the endometrial growth that occurs during transition from the diestrus to estrous stage. This transition is under control of 17beta-estradiol (E2), an ovarian hormone, and can be mimicked by injection of E2 to ovariectomized (OVX) mouse. Thus, the uterus is a pertinent site to examine the Epo function in angiogenesis. We found that Epo protein and its mRNA were produced in an E2-dependent manner, when the uterus from OVX mouse was cultured in vitro. The de novo protein synthesis was not needed for E2 induction of Epo mRNA. Administration of E2 to OVX mouse induced a rapid and transient increase in Epo mRNA in the uterus. Injection of Epo into the OVX mouse uterine cavity promoted blood vessel formation in the endometrium. Furthermore, injection of the soluble Epo receptor capable of binding with Epo into the uterine cavity of non-OVX mouse in diestrus stage inhibited the endometrial transition to proestrus stage, whereas heat-inactivated soluble Epo receptor allowed the transition to occur. These results, combined with our finding that the endothelial cells in uterine endometrium express Epo receptor, strongly suggest that Epo is an important factor for the E2-dependent cyclical angiogenesis in uterus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738005     DOI: 10.1074/jbc.273.39.25381

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin.

Authors:  F T Ruschitzka; R H Wenger; T Stallmach; T Quaschning; C de Wit; K Wagner; R Labugger; M Kelm; G Noll; T Rülicke; S Shaw; R L Lindberg; B Rodenwaldt; H Lutz; C Bauer; T F Lüscher; M Gassmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Authors:  Ahmed Mohyeldin; Huasheng Lu; Clifton Dalgard; Stephen Y Lai; Noam Cohen; Geza Acs; Ajay Verma
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.

Authors:  Ping Fu; Murat O Arcasoy
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

Review 4.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 5.  Erythropoietic agents and the elderly.

Authors:  Neeraj Agarwal; Josef T Prchal
Journal:  Semin Hematol       Date:  2008-10       Impact factor: 3.851

6.  Reticulocyte profile in top-level alpine skiers during four consecutive competitive seasons.

Authors:  Giuseppe Banfi; Rodolfo Tavana; Marco Freschi; Carsten Lundby
Journal:  Eur J Appl Physiol       Date:  2010-02-12       Impact factor: 3.078

7.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

8.  Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal.

Authors:  Bing Zhou; Jeffrey S Damrauer; Sean T Bailey; Tanja Hadzic; Youngtae Jeong; Kelly Clark; Cheng Fan; Laura Murphy; Cleo Y Lee; Melissa A Troester; C Ryan Miller; Jian Jin; David Darr; Charles M Perou; Ross L Levine; Maximilian Diehn; William Y Kim
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

9.  A novel role for erythropoietin during fibrin-induced wound-healing response.

Authors:  Zishan A Haroon; Khalid Amin; Xiaohong Jiang; Murat O Arcasoy
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.

Authors:  Fabian Sanchis-Gomar; Carme Perez-Quilis; Giuseppe Lippi
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.